Journal Article

Identification of ITIAM1/I as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma

Casement, John, Permtermsin, Chalermsin, Ogle, Laura Frances, Strathdee, Gordon, Reeves, Helen L, Lalchungnunga, H, Shukla, Ruchi, Nakjang, Sirintra

2023

Overview

Hepatocellular carcinoma (HCC), the most common type of liver cancer, has very poor outcomes. Current therapies often have low efficacy and significant toxicities. Thus, there is a critical need for the development of novel therapeutic approaches for HCC. We have developed a novel bioinformatics pipeline, which integrates genome-wide DNA methylation and gene expression data, to identify genes required for the survival of specific molecular cancer subgroups but not normal cells. Targeting these genes may induce cancer-specific \"synthetic lethality\". Initially, five potential HCC molecular subgroups were identified based on global DNA methylation patterns. Subgroup-2 exhibited the most unique methylation profile and two candidate subtype-specific vulnerability or SL-like genes were identified for this subgroup, including TIAM1, a guanine nucleotide exchange factor encoding gene known to activate Rac1 signalling. siRNA targeting TIAM1 inhibited cell proliferation in TIAM1-positive (subgroup-2) HCC cell lines but had no effect on the normal hepatocyte HHL5 cell line. Furthermore, TIAM1-positive/subgroup-2 cell lines were significantly more sensitive to the TIAM1/RAC1 inhibitor NSC23766 compared with TIAM1-negative HCC lines or the normal HHL5 cell line. The results are consistent with a synthetic lethal role for TIAM1 in a methylation-defined HCC subgroup and suggest it may be a viable therapeutic target in this subset of HCC patients.

• Publisher: MDPI AG
• Subject: Cancer / Gene expression / Genes / Genetic aspects / Genomes / Genomics / Health aspects / Hepatoma / Liver / Methylation / Type 2 diabetes